PRME
Price
$1.46
Change
-$0.07 (-4.58%)
Updated
Jun 12 closing price
Capitalization
200.88M
54 days until earnings call
VSTM
Price
$5.88
Change
-$0.09 (-1.51%)
Updated
Jun 12 closing price
Capitalization
323.1M
Interact to see
Advertisement

PRME vs VSTM

Header iconPRME vs VSTM Comparison
Open Charts PRME vs VSTMBanner chart's image
Prime Medicine
Price$1.46
Change-$0.07 (-4.58%)
Volume$991.83K
Capitalization200.88M
Verastem
Price$5.88
Change-$0.09 (-1.51%)
Volume$1.62M
Capitalization323.1M
PRME vs VSTM Comparison Chart
Loading...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VSTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PRME vs. VSTM commentary
Jun 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRME is a Buy and VSTM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 13, 2025
Stock price -- (PRME: $1.46 vs. VSTM: $5.88)
Brand notoriety: PRME and VSTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRME: 48% vs. VSTM: 86%
Market capitalization -- PRME: $200.88M vs. VSTM: $323.1M
PRME [@Biotechnology] is valued at $200.88M. VSTM’s [@Biotechnology] market capitalization is $323.1M. The market cap for tickers in the [@Biotechnology] industry ranges from $352B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRME’s FA Score shows that 0 FA rating(s) are green whileVSTM’s FA Score has 0 green FA rating(s).

  • PRME’s FA Score: 0 green, 5 red.
  • VSTM’s FA Score: 0 green, 5 red.
According to our system of comparison, PRME is a better buy in the long-term than VSTM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRME’s TA Score shows that 5 TA indicator(s) are bullish while VSTM’s TA Score has 4 bullish TA indicator(s).

  • PRME’s TA Score: 5 bullish, 4 bearish.
  • VSTM’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, PRME is a better buy in the short-term than VSTM.

Price Growth

PRME (@Biotechnology) experienced а +7.35% price change this week, while VSTM (@Biotechnology) price change was -4.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.74%. For the same industry, the average monthly price growth was +15.53%, and the average quarterly price growth was +6.63%.

Reported Earning Dates

PRME is expected to report earnings on Aug 06, 2025.

VSTM is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (+4.74% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VSTM($323M) has a higher market cap than PRME($201M). VSTM YTD gains are higher at: 13.733 vs. PRME (-50.000). VSTM has higher annual earnings (EBITDA): -88.92M vs. PRME (-200M). PRME has more cash in the bank: 144M vs. VSTM (113M). VSTM has less debt than PRME: VSTM (41.4M) vs PRME (121M). VSTM has higher revenues than PRME: VSTM (10M) vs PRME (3.85M).
PRMEVSTMPRME / VSTM
Capitalization201M323M62%
EBITDA-200M-88.92M225%
Gain YTD-50.00013.733-364%
P/E RatioN/AN/A-
Revenue3.85M10M38%
Total Cash144M113M127%
Total Debt121M41.4M292%
FUNDAMENTALS RATINGS
PRME vs VSTM: Fundamental Ratings
PRME
VSTM
OUTLOOK RATING
1..100
364
VALUATION
overvalued / fair valued / undervalued
1..100
38
Fair valued
81
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
6453
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (38) in the null industry is somewhat better than the same rating for VSTM (81) in the Biotechnology industry. This means that PRME’s stock grew somewhat faster than VSTM’s over the last 12 months.

PRME's Profit vs Risk Rating (100) in the null industry is in the same range as VSTM (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to VSTM’s over the last 12 months.

PRME's SMR Rating (96) in the null industry is in the same range as VSTM (97) in the Biotechnology industry. This means that PRME’s stock grew similarly to VSTM’s over the last 12 months.

VSTM's Price Growth Rating (53) in the Biotechnology industry is in the same range as PRME (64) in the null industry. This means that VSTM’s stock grew similarly to PRME’s over the last 12 months.

VSTM's P/E Growth Rating (100) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that VSTM’s stock grew similarly to PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PRMEVSTM
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
78%
Momentum
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
81%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 8 days ago
77%
Bullish Trend 8 days ago
85%
Declines
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
87%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VSTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FRINX12.08N/A
N/A
Fidelity Advisor Real Estate Income A
GPGOX3.53N/A
N/A
Grandeur Peak Global Opportunities Inv
CAFRX9.37N/A
N/A
Commonwealth Africa
PKAIX13.53N/A
N/A
PIMCO RAE US Instl
IVNQX45.04N/A
N/A
Invesco Nasdaq 100 Index R6

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-4.58%
CRSP - PRME
63%
Loosely correlated
-0.58%
BEAM - PRME
57%
Loosely correlated
-2.52%
RXRX - PRME
57%
Loosely correlated
-4.26%
CRBU - PRME
51%
Loosely correlated
-1.69%
IPSC - PRME
50%
Loosely correlated
-1.01%
More

VSTM and

Correlation & Price change

A.I.dvisor indicates that over the last year, VSTM has been loosely correlated with ZLDAF. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if VSTM jumps, then ZLDAF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VSTM
1D Price
Change %
VSTM100%
-1.51%
ZLDAF - VSTM
47%
Loosely correlated
N/A
SNSE - VSTM
47%
Loosely correlated
+2.63%
IPSC - VSTM
39%
Loosely correlated
-1.01%
IMNM - VSTM
39%
Loosely correlated
+3.16%
PRME - VSTM
38%
Loosely correlated
-4.58%
More